Unknown

Dataset Information

0

Long-term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.


ABSTRACT: We evaluated antibody persistence against hepatitis B virus (HBV) in adolescents previously vaccinated with a hexavalent diphtheria-tetanus-acellular pertussis-HBV-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine (DTPa-HBV-IPV/Hib), as part of the national newborn immunization program in Germany. We also assessed the anamnestic response to a challenge dose of a monovalent HBV vaccine. In this phase 4, open-label, non-randomized study (NCT02798952), 302 adolescents aged 14-15 years, primed in their first 2 years of life with 4 DTPa-HBV-IPV/Hib doses, received one challenge dose of monovalent HBV vaccine. Blood samples were taken before and one month post-vaccination and used to determine antibody levels against hepatitis B surface antigen (HBs). Reactogenicity and safety were also assessed post-challenge dose. Pre-challenge dose, 53.7% of 268 participants included in the according-to-protocol cohort for immunogenicity had anti-HBs antibody concentrations ?10 mIU/mL (seroprotection cut-off) and 16.8% had anti-HBs antibody concentrations ?100 mIU/mL. One month post-challenge dose, 93.3% of adolescents had anti-HBs antibody concentrations ?10 mIU/mL and 87.3% had antibody concentrations ?100 mIU/mL. An anamnestic response was mounted in 92.5% of adolescents. Injection site pain (in 33.6% of participants) and fatigue (30.2%) were the most frequently reported solicited local and general symptoms, respectively. Six of the 55 unsolicited adverse events reported were considered vaccination-related. Two vaccination-unrelated serious adverse events were reported during the study. Long-term antibody persistence against hepatitis B was observed in 14-15 years old adolescents previously primed in infancy with DTPa-HBV-IPV/Hib. A challenge dose of monovalent HBV vaccine induced strong anamnestic response, with no safety concerns.

SUBMITTER: Schwarz TF 

PROVIDER: S-EPMC6363144 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.

Schwarz Tino F TF   Behre Ulrich U   Adelt Thomas T   Donner Matthias M   Suryakiran Pemmaraju V PV   Janssens Winnie W   Mesaros Narcisa N   Panzer Falko F  

Human vaccines & immunotherapeutics 20180911 1


We evaluated antibody persistence against hepatitis B virus (HBV) in adolescents previously vaccinated with a hexavalent diphtheria-tetanus-acellular pertussis-HBV-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine (DTPa-HBV-IPV/Hib), as part of the national newborn immunization program in Germany. We also assessed the anamnestic response to a challenge dose of a monovalent HBV vaccine. In this phase 4, open-label, non-randomized study (NCT02798952), 302 adolescents aged 14-1  ...[more]

Similar Datasets

| S-EPMC5443106 | biostudies-literature
| S-EPMC5396237 | biostudies-literature
| S-EPMC5287296 | biostudies-literature
| S-EPMC2821389 | biostudies-literature
| S-EPMC5512790 | biostudies-literature
| S-EPMC5360111 | biostudies-literature
| S-EPMC6422512 | biostudies-literature
| S-EPMC3426081 | biostudies-literature
| S-EPMC4974178 | biostudies-literature
| S-EPMC1940311 | biostudies-literature